SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
GERN

Geron Corp (NASDAQ:GERN)

US · Delayed Price · Currency is USD
Also listed: 0IV3.LHealthcare · Biotechnology
$0.87-$0.04 (-4.63%)
 
Market cap
$561M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 31, 1996
Website
Market Cap$560.94M-24.9%
Revenue (ttm)$217.52M+18.6%
Net Income-$50.12M+37.3%
EPS-$0.07+42.3%
Shares Out644.24M
PE Ration/a
Forward PE10.24
Dividendn/a
Ex-Dividend Daten/a
Volume13,832,347
Open$0.89
Previous Close$0.91
Day's Range$0.86 - $0.93
52-Week Range$0.84 - $2.01
Beta0.61
AnalystsBuy
Price Target$5.89(+576.47%)
Earnings DateFeb 24, 2027

About GERN

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Address
919 East Hillsdale Boulevard, Foster City, CA, 94404, US
Market Cap
561 million
Employees
258
Industrial Classification
Biotechnology

Geron Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
83rd Percentile Overall Score
GERN InsiderScore:88 / 99

Geron Corp scored higher than 83% of companies evaluated by InsiderBuying, and ranked 16th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Geron Corp bought $62.1K of stock across 2 purchases in the last 90 days, the largest of them $50.8K.

Stake Increase

None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.

New Positions

2 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$19.12K
Bought
$62.10K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 Sell

2 firms rating GERN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From GERN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-4.63%
5 Days
-9.03%
1 Month
-22.95%
6 Months
-31.98%
1 Year
-24.94%

$GERN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in GERN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by GERN's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

GERN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

GERN Revenue by Segment

$65.99MTotal
Product revenue, net$60.11M91.10%
Income (loss) from operations$5.80M8.79%
Royalties$76.00K0.12%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New GERN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to GERN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in GERN

XBIState Street SPDR S&P Biotech ETF$16.90M
VTIVanguard Morningstar Total Stock Market ETF$14.38M
IWMiShares Russell 2000 ETF$12.80M
VXFVanguard Extended Market ETF$5.94M
IWOiShares Russell 2000 Growth ETF$4.85M
IBBiShares Biotechnology ETF$4.29M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from GERN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
65.09
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
62

News check: RYTELO sales growth and Germany expansion represent positive concrete business developments, offset by stock price decline and investor disappointment.

Recent Insider Activity

Buys
2
Sells
1
Buy Value
$62.10K
Distinct Buyers
2

Insider Score Trend Over Time

-3.8 since Nov 17
0255075100Nov 17 — Insider Score 91.5Nov 18 — Insider Score 90.5Nov 19 — Insider Score 89.3Nov 20 — Insider Score 88.3Nov 21 — Insider Score 87.5Nov 22 — Insider Score 87.7Nov 17Nov 19Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBPVirtus Biotech ETF1.14%
SBIOALPS Medical Breakthroughs ETF0.42%
WDNAWisdomTree BioRevolution Fund0.40%
QQQSInvesco NASDAQ Future Gen 200 ETF0.39%
XBIState Street SPDR S&P Biotech ETF0.18%
ESSCEventide Small Cap ETF0.10%
FSEGFidelity Enhanced Small Cap Growth ETF0.07%
VTWGVanguard Russell 2000 Growth ETF0.04%
IBBiShares Biotechnology ETF0.04%
IBBQInvesco Nasdaq Biotechnology ETF0.04%
IWOiShares Russell 2000 Growth ETF0.04%
PWSPacer WealthShield ETF0.04%

Weight is the stock’s share of each fund’s holdings.